Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK tech assessment

This article was originally published in The Gray Sheet

Executive Summary

Stakeholders affected by the impending seventh wave of the National Institute for Clinical Excellence work program should complete the NICE 1registration form before timetables are announced at the end of June. The UK Department of Health and the Welsh Assembly Government identify stakeholders as: patient organizations; health professional groups; and manufacturers with technologies in the clinical area covered by the scope of the program guidelines. Primary care organizations and acute trusts will be selected at random and invited to participate. NICE says that the assessment will include drug-eluting stent performance for atherosclerotic events and the prevention of restenosis (2"The Gray Sheet" May 27, 2002, p. 10)...

You may also be interested in...



Drug-Eluting Stents Added To NICE Technology Appraisal Program In UK

The UK National Institute for Clinical Excellence will release its timetable for a drug-eluting stent technology assessment by the end of June, according to Chief Executive Andrew Dillon

Coronavirus Update: SK Bioscience, Biological E, DongWha And Celltrion Report Progress

SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.

COVID-19: Could Lateral Flow Test Using Glycan Recognition Be A Rapid Testing Breakthrough?

UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel